Phase 1 Dose Escalation Study for VIP943 Subjects With Advanced CD123+ Hematologic Malignancies

Conditions:   Acute Myeloid Leukemia;   B-cell Acute Lymphoblastic Leukemia;   High-risk Myelodysplastic Syndrome Intervention:   Drug: VIP943 Sponsor:   Vincerx Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials